StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback